Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,054 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma.
Hippo Y, Watanabe K, Watanabe A, Midorikawa Y, Yamamoto S, Ihara S, Tokita S, Iwanari H, Ito Y, Nakano K, Nezu J, Tsunoda H, Yoshino T, Ohizumi I, Tsuchiya M, Ohnishi S, Makuuchi M, Hamakubo T, Kodama T, Aburatani H. Hippo Y, et al. Among authors: yoshino t. Cancer Res. 2004 Apr 1;64(7):2418-23. doi: 10.1158/0008-5472.can-03-2191. Cancer Res. 2004. PMID: 15059894
Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells.
Nakano K, Orita T, Nezu J, Yoshino T, Ohizumi I, Sugimoto M, Furugaki K, Kinoshita Y, Ishiguro T, Hamakubo T, Kodama T, Aburatani H, Yamada-Okabe H, Tsuchiya M. Nakano K, et al. Among authors: yoshino t. Biochem Biophys Res Commun. 2009 Jan 9;378(2):279-84. doi: 10.1016/j.bbrc.2008.11.033. Epub 2008 Nov 18. Biochem Biophys Res Commun. 2009. PMID: 19022220
Viral envelope protein gp64 transgenic mouse facilitates the generation of monoclonal antibodies against exogenous membrane proteins displayed on baculovirus.
Saitoh R, Ohtomo T, Yamada Y, Kamada N, Nezu J, Kimura N, Funahashi S, Furugaki K, Yoshino T, Kawase Y, Kato A, Ueda O, Jishage K, Suzuki M, Fukuda R, Arai M, Iwanari H, Takahashi K, Sakihama T, Ohizumi I, Kodama T, Tsuchiya M, Hamakubo T. Saitoh R, et al. Among authors: yoshino t. J Immunol Methods. 2007 Apr 30;322(1-2):104-17. doi: 10.1016/j.jim.2007.02.005. Epub 2007 Mar 7. J Immunol Methods. 2007. PMID: 17374538
Olaparib with or without bevacizumab versus bevacizumab plus a fluoropyrimidine as maintenance therapy in advanced colorectal cancer: The randomized phase 3 LYNK-003 study.
Takashima A, García-Alfonso P, Manneh R, Beşen AA, Hong YS, Cuyle PJ, Yanez P, Burge M, Yoshino T, Kim TW, Cui K, Li C, Jain R, Adelberg D, Taieb J. Takashima A, et al. Among authors: yoshino t. Eur J Cancer. 2024 Mar 21;205:114036. doi: 10.1016/j.ejca.2024.114036. Online ahead of print. Eur J Cancer. 2024. PMID: 38749110 Free article.
Genomic Landscape of Circulating Tumor DNA in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Treated With Abemaciclib: Data From the SCRUM-Japan Cancer Genome Screening Project.
Hattori M, Serelli-Lee V, Naito Y, Yamanaka T, Yasojima H, Nakamura R, Fujisawa T, Imai M, Nakamura Y, Bando H, Kawaguchi T, Yoshino T, Iwata H. Hattori M, et al. Among authors: yoshino t. JCO Precis Oncol. 2024 Apr;8:e2300647. doi: 10.1200/PO.23.00647. JCO Precis Oncol. 2024. PMID: 38635933
Phase II trial of niraparib for BRCA-mutated biliary tract, pancreatic and other gastrointestinal cancers: NIR-B.
Kawamoto Y, Morizane C, Komatsu Y, Kondo S, Ueno M, Kobayashi S, Furukawa M, Lee L, Satoh T, Sakai D, Ikeda M, Imaoka H, Miura A, Hatanaka Y, Yokota I, Nakamura Y, Yoshino T. Kawamoto Y, et al. Among authors: yoshino t. Future Oncol. 2024 Apr 17. doi: 10.2217/fon-2023-0348. Online ahead of print. Future Oncol. 2024. PMID: 38629456 Free article. Review.
2,054 results